| Name | LC-MB12 |
|---|---|
| Synonyms |
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-{1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperidine-4-carbonyl}piperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea
N′-(2,6-Dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-[4-[[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-4-piperidinyl]carbonyl]-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]-N-methylurea Urea, N′-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-[4-[[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-4-piperidinyl]carbonyl]-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]-N-methyl 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4-carbonyl)piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea |
| Description | LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. LC-MB12 contains BGJ398 (a FGFR2 inhibitor), PROTAC linker and CRBN.LC-MB12 inhibits FGFR2 signaling in gastric cancer cells and has anti-tumor activity[1]. |
|---|---|
| Related Catalog | |
| Target |
FGFR2:11.8 nM (DC50) |
| References |
| Molecular Formula | C43H44Cl2N10O8 |
|---|---|
| Molecular Weight | 899.78 |